You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 78 No. 1, January 1959 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Reversal by Ipsilon of Lytic System in Blood Stream Produced in Rabbits by Streptokinase

JOSEPH M. MILLER, M.D.; DANIEL R. ROBINSON, M.D.; DEBORAH A. JACKSON, B.S.; CHARLES S. COLLIER

AMA Arch Surg. 1959;78(1):33-36.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Ipsilon ({varepsilon}-amino-caproic acid) has been reported to have the ability to inhibit completely at a small concentration the activity of plasmin.3 The measurement of antiplasmin power in that investigation was studied by using fibrin clots.

The capacity of Ipsilon to inhibit a lytic system in the blood stream may have considerable promise in clinical medicine. The drug may provide a means of producing coagulation of the blood in patients whose clots undergo spontaneous lysis. Ipsilon might also serve as an antidote in patients who have had a lytic system established by streptokinase for the treatment of thrombosis. A conceivable extension of the use of streptokinase would be to produce an incoagulable blood in patients undergoing cardiac surgery when the heart-lung machine is used with the lytic system reversed by Ipsilon. The many clinical uses to which the drug could be put, particularly to inhibit the effects produced by streptokinase . . . [Full Text PDF of this Article]


Author Affiliations

Fort Howard, Md.

Surgical Service, Veterans' Administration Hospital, Fort Howard, Md., and Department of Surgery, The Johns Hopkins School of Medicine, Baltimore (Dr. Miller). Veterans' Administration Hospital (Dr. Robinson); General Medical Research Service, Veterans' Administration Hospital (Miss Jackson); General Medical Research Service, Veterans' Administration Hospital (Mr. Collier), Fort Howard, Md.


Footnotes

Submitted for publication July 28, 1958.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1959 American Medical Association. All Rights Reserved.